Novartis’ newly acquired melanoma combo wins EU recommendation

Carly Helfand

' recently duo, Tafinlar and Mekinist, has won a from the European Medicines Agency's Committee for Medicinal Products for Human Use as a treatment for BRAF V600 mutation-positive melanoma

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS